Trials / Completed
CompletedNCT00631943
A Study to Evaluate the Efficacy and Safety of Pregabalin (Lyrica) for the Treatment of Nerve Pain
An Open Label, Non-comparative, Multicentre Study to Evaluate the Efficacy and Tolerability of Pregabalin in Peripheral Neuropathic Pain
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 112 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of Lyrica in Indian patients with nerve pain
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pregabalin (Lyrica) | Oral pregabalin (Lyrica) capsules, initial dose of 75 mg twice daily, which could be increased to 300 mg twice daily at the discretion of the investigator. Patients were treated for up to 21 days. |
Timeline
- Start date
- 2004-11-01
- Completion
- 2005-03-01
- First posted
- 2008-03-10
- Last updated
- 2021-01-22
Locations
6 sites across 1 country: India
Source: ClinicalTrials.gov record NCT00631943. Inclusion in this directory is not an endorsement.